Global Chronic myeloid leukemia (CML) Market Research Report

Key Questions Answered

• What are market estimates and forecasts; which of Chronic myeloid leukemia (CML) markets are doing well and which are not?
• What is the competitive landscape; How companies like Pfizer Inc, Novartis AG and ARIAD Pharmaceuticals Inc doing in Chronic myeloid leukemia (CML)?

 

What makes our report unique?

• This reports provides most granular segmentation on Chromatography, E-Clinical Trial Solutions, Wireless Health and Clinical Trial Management Systems (CTMS).
• This report provides market sizing and forecast for the Chronic myeloid leukemia (CML) market. It also provides market sizing and forecast along with the drivers/inhibitors/opportunity analysis for each of the micro markets.
• The report provides deep dive competitive landscape covering the top players such as Pfizer Inc, Novartis AG, ARIAD Pharmaceuticals Inc and BRISTOL-MYERS SQUIBB.
• The reports provides benchmarking insight on the top players Pfizer Inc, Novartis AG, ARIAD Pharmaceuticals Inc and BRISTOL-MYERS SQUIBB.
• The report provide competitive intelligence on Pfizer Inc, Novartis AG, ARIAD Pharmaceuticals Inc and BRISTOL-MYERS SQUIBB.

 

Audience for this report

• Global Chronic myeloid leukemia (CML) companies
• Manufacturing Companies
• Traders, distributors, and suppliers
• Governmental and research organizations
• Associations and industry bodies
• Technology providers

 

Top developments

• European Medicines Agency accepted Pfizer's regulatory submissions for review of bosutinib(drug)
• Bristol-Myers and Innate Pharma S.A. (France) entered into an agreement to develop and market Phase I drug, IPH2102, human monoclonal antibody for cancer treatment
• Bristol-Myers Squibb and Otsuka Pharmaceutical Co. Ltd. declared 18-month follow-up results for Phase III DASISION study of Sprycel versus imatinib for the treatment of adults with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
• InVivoScribe Technologies Inc. and Novartis collaborated to develop and market a companion diagnostic test
• Novartis obtained Canada healthcare authority approval for Tasigna
• Bristol-Myers Squibb and Otsuka America Pharmaceutical Inc. declared five-year follow-up results from Phase III study of Sprycel in Philadelphia
• The company collaborated with MolecularMD Corporation (U.S.)
• Novartis received approval for Tasigna as first-line therapy for the treatment of chronic myelogenous leukemia patient in Japan.
• Novartis received Japan's Ministry of Health, Labour and Welfare’s approval for Tasigna (nilotinib)
• Bristol-Myers Squibb obtained European Commission Marketing Authorization for Sprycel (dasatinib) for the treatment of adult Philadelphia chromosome positive chronic myelogenous leukemia in the chronic phase.

Please fill in the form below to receive a free copy of the Summary of this Report

* First Name :

* Last Name :

* Designation :

* Company :

* Email(Username) :

* Phone :

* Country :

-- Select Country -- India Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antigua Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia Herzegovina Botswana Brazil British Virgin Island Brunei Darussalam Bulgaria Burkina Faso Burundi Cote d'Ivoire Cambodia Cameroon Canada Cape Verde Cayman Isls Central African Republic Chad Chile China Colombia Comoros Congo Cook Island Costa Rica Croatia Cuba Cyprus Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Falkland Islands (Malvinas) Fiji Finl France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenl Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Holy See Honduras Hong Kong Special Administrative Hungary Iceland Indonesia Iran (Islamic Republic of Iran) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Special Administrative Region of China Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Micronesia Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherland Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Islands Northern Mariana Islands Norway Occupied Palestinian Territory Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Republic of Korea Republic of Moldova Romania Russian Federation Rwa Saint Helena Saint Kitts Nevis Saint Lucia Saint Pierre Miquelon Saint Vincent the Grenadines Samoa San Marino Sao Tome Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Suriname Svalbard Jan Mayen Islands Swazil Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Thailand The former Yugoslav Republic of Macedonia Timor-Leste Togo Tokelau Tonga Trinidad Tobago Tunisia Turkey Turkmenistan Turks Caicos Isls Tuvalu Uga Ukraine United Arab Emirates United Kingdom United Republic of Tanzania United States United States Virgin Isls Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Wallis Futuna Isls Western Sahara Yemen Yugoslavia Zambia Zimbabwe

Comments :

Reports Interested in :Global Chronic myeloid leukemia (CML) Market Research Report

* Enter the text from the image to the text box :